A Study of LY4065967 in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

March 11, 2025

Study Completion Date

March 11, 2025

Conditions

Healthy

Interventions

DRUG

LY4065967

Administered orally

DRUG

Placebo

Administered orally

DRUG

Rosuvastatin

Administered orally

Trial Locations (1)

Souseikai Fukuoka Mirai Hospital, Fukuoka

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06594159 - A Study of LY4065967 in Healthy Japanese Participants | Biotech Hunter | Biotech Hunter